FDA authorizes limited prescriptions of Paxlovid by pharmacists

The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization.
Related News Articles
Headline
AHA’s United Against the Flu campaign today released a new social media toolkit to help hospitals and health systems encourage their communities to get…
Headline
The Food and Drug Administration today released final guidance for transitioning medical device enforcement policies and emergency use authorizations…
Headline
Candida auris fungal infections tripled in the United States between 2019 and 2021 to 1,471, including seven cases resistant to all antifungal treatments,…
Headline
The Food and Drug Administration Friday authorized for emergency use a molecular test to detect mpox (formerly known as monkeypox) at the point of care in…
Headline
The Food and Drug Administration will end 22 COVID-19-related policies when the public health emergency ends May 11 and allow 22 to continue for 180 days,…
Chairperson's File
March 12–18 is Patient Safety Awareness Week. While patient safety is a priority every day of the year for teams working at our nation’s hospitals and health…